Archives
-
KU-60019: ATM Inhibition in Cancer Research
2026-10-04
KU-60019 is a research compound used to study ATM kinase signaling, DNA damage response inhibition, radiosensitization, and cancer-cell adaptation. This overview separates supplier-reported properties from findings in a peer-reviewed study linking ATM suppression to macropinocytosis and nutrient scavenging. It compares the strength of biochemical, cellular, animal, and metabolic evidence while outlining limitations, including uncertainty about whether findings from broader ATM-suppression models apply specifically to KU-60019 or to glioma.
-
CFDA-SE and the CD38 Surfaceome: Research Context
2026-10-03
CFDA-SE is a division-sensitive fluorescent labeling reagent, while nanobody-targeted TurboID maps proteins near a defined cell-surface target. This overview compares what each method measures, explains how they could be interpreted together in conceptual studies, and reviews findings from Feng et al. on the CD38-associated surfaceome. It also highlights source provenance, model-specific limitations, and why fluorescence dilution, proximity labeling, migration, and proliferation should not be treated as interchangeable evidence.
-
U-73122: Phospholipase C Inhibitor Workflows
2026-10-02
U-73122 gives researchers a practical way to test PLC-dependent calcium flux, chemotaxis, and cancer-cell invasion in controlled cellular workflows. This guide connects concentration planning and assay troubleshooting with findings from breast cancer invasion research while separating established evidence from experimental starting conditions.
-
KU-55933 ATM Kinase Inhibitor: Assay Workflow
2026-10-01
Build cleaner DNA damage response research around KU-55933 with a practical workflow spanning phospho-Akt signaling, cell cycle arrest induction, proliferation, and cancer-cell metabolism. The guide also translates a recent cGAS–TRIM41–ORF2p study into testable assay choices while separating established product evidence from forward-looking hypotheses.
-
Trichostatin A and the HDAC3–Ferroptosis Axis
2026-10-01
Trichostatin A (TSA) offers a practical route to interrogate how histone deacetylase activity shapes cancer-cell state. This thought-leadership article connects TSA-based epigenetic perturbation with the HDAC3–NRF2–GPX4 ferroptosis axis in colorectal cancer, while outlining controls, protocol considerations, translational limits, and opportunities for better mechanistic validation.
-
AZD3463: ALK/IGF1R Inhibitor for Neuroblastoma
2026-09-30
AZD3463 is an orally bioavailable ALK/IGF1R inhibitor investigated in preclinical ALK-driven cancer research. Reported activity includes inhibition of wild-type and mutant ALK, ALK-mediated PI3K/AKT/mTOR pathway inhibition, neuroblastoma apoptosis induction, and tumor-growth reduction in orthotopic mouse models.
-
LY294002: PI3K/Akt/mTOR Assay Workflows
2026-09-30
Build reproducible PI3K/Akt/mTOR, macrophage-polarization, apoptosis, and autophagy assays with LY294002 while accounting for reversibility and micromolar off-target activity. This workflow translates an allergic-asthma signaling study into practical cell-based experiments without overstating what the reference study directly demonstrated.
-
KU-60019: Strategic ATM Inhibition in Glioma
2026-09-29
A translational framework for using KU-60019 as a selective ATM kinase inhibitor, with emphasis on glioma radiosensitization, invasion biology, experimental controls, metabolic context, and evidence-based development strategy.
-
NU7441 (KU-57788) DNA-PK Inhibitor Guide
2026-09-29
NU7441, also called KU-57788, is an ATP-competitive DNA-PK inhibitor with a reported DNA-PK IC50 of approximately 13–14 nM. This guide separates product-reported potency and workflow parameters from peer-reviewed evidence on DNA damage response, telomere maintenance, and oncology research.
-
MG-132 (Z-LLL-al) Workflow for Proteasome Studies
2026-09-28
MG-132 (Z-LLL-al) provides a fast, cell-permeable way to connect proteasome blockade with protein accumulation, apoptosis, oxidative stress, and cell-cycle phenotypes. This practical guide translates the FGF19–TRIM21–ANXA2 findings in nasopharyngeal carcinoma into assay designs, controls, and troubleshooting steps for cancer research.
-
KU-60019: ATM Kinase Inhibitor for Glioma Research
2026-09-28
KU-60019 is a potent ATM kinase inhibitor used to investigate DNA damage response signaling and glioma radiosensitization. Product information reports selective ATM inhibition and glioma-cell effects, while a separate study links ATM inhibition to macropinocytosis in other cancer models.
-
Cy3 Goat Anti-Human IgG (H+L): Signal to Inference
2026-09-27
The Cy3 Goat Anti-Human IgG (H+L) Antibody supports fluorescent detection of human IgG, but choosing the right detection reagent also depends on species, assay purpose, and biological interpretation. Using recent orthopoxvirus antibody research as a case study, this article explains where a Cy3 conjugated secondary antibody fits—and where it does not.
-
Lamotrigine B2249: Reliable Cell Assay Design
2026-09-26
A practical, evidence-led guide to using Lamotrigine (SKU B2249) in viability, proliferation, and cytotoxicity workflows without confusing assay interference with biological effects. Covers mechanism-aware controls, stock preparation, interpretation limits, and product selection.
-
Meropenem Trihydrate for Resistance Phenotyping
2026-09-25
Meropenem trihydrate is a carbapenem antibiotic useful for studying bacterial susceptibility and resistance. This article explains how to pair its controlled use with antibiotic-free metabolomic profiling while keeping baseline resistance signatures distinct from drug-response effects.
-
5-Aminolevulinic acid HCl in Heme Pathway Assays
2026-09-25
Use 5-Aminolevulinic acid HCl as a defined pathway-entry perturbation—not as a substitute for heme—to test how tetrapyrrole flux relates to Salmonella phagocytosis resistance. The same precursor also supports distinct cancer research workflows involving protoporphyrin IX, photodynamic therapy, and fluorescence-guided tumor resection.